Literature DB >> 29967074

Stop fRETting the Target: Next-Generation RET Inhibitors Have Arrived.

Wade T Iams1, Christine M Lovly2.   

Abstract

BLU-667 is a next-generation RET inhibitor that maximizes on-target and minimizes off-target effects. It is an exemplar of genotype-driven drug development followed by multi-histology basket trial validation that is becoming a paradigm for precision oncology. Cancer Discov; 8(7); 797-9. ©2018 AACRSee related article by Subbiah et al., p. 836. ©2018 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29967074      PMCID： PMC6345252          DOI： 10.1158/2159-8290.CD-18-0489

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  10 in total

Review 1.  The rapidly evolving therapies for advanced melanoma--Towards immunotherapy, molecular targeted therapy, and beyond.

Authors:  Ziqiang Zhu; Wei Liu; Vladimir Gotlieb
Journal:  Crit Rev Oncol Hematol       Date:  2015-12-10       Impact factor: 6.312

2.  Precision Targeted Therapy with BLU-667 for RET-Driven Cancers.

Authors:  Vivek Subbiah; Justin F Gainor; Rami Rahal; Jason D Brubaker; Joseph L Kim; Michelle Maynard; Wei Hu; Qiongfang Cao; Michael P Sheets; Douglas Wilson; Kevin J Wilson; Lucian DiPietro; Paul Fleming; Michael Palmer; Mimi I Hu; Lori Wirth; Marcia S Brose; Sai-Hong Ignatius Ou; Matthew Taylor; Elena Garralda; Stephen Miller; Beni Wolf; Christoph Lengauer; Timothy Guzi; Erica K Evans
Journal:  Cancer Discov       Date:  2018-04-15       Impact factor: 39.397

3.  Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).

Authors:  Alexander Drilon; Salvatore Siena; Sai-Hong Ignatius Ou; Manish Patel; Myung Ju Ahn; Jeeyun Lee; Todd M Bauer; Anna F Farago; Jennifer J Wheler; Stephen V Liu; Robert Doebele; Laura Giannetta; Giulio Cerea; Giovanna Marrapese; Michele Schirru; Alessio Amatu; Katia Bencardino; Laura Palmeri; Andrea Sartore-Bianchi; Angelo Vanzulli; Sara Cresta; Silvia Damian; Matteo Duca; Elena Ardini; Gang Li; Jason Christiansen; Karey Kowalski; Ann D Johnson; Rupal Patel; David Luo; Edna Chow-Maneval; Zachary Hornby; Pratik S Multani; Alice T Shaw; Filippo G De Braud
Journal:  Cancer Discov       Date:  2017-02-09       Impact factor: 39.397

4.  Differential Sensitivity to Crizotinib: Does EML4-ALK Fusion Variant Matter?

Authors:  Jessica J Lin; Alice T Shaw
Journal:  J Clin Oncol       Date:  2016-07-25       Impact factor: 44.544

5.  Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer.

Authors:  Ryan B Corcoran; Thierry André; Chloe E Atreya; Jan H M Schellens; Takayuki Yoshino; Johanna C Bendell; Antoine Hollebecque; Autumn J McRee; Salvatore Siena; Gary Middleton; Kei Muro; Michael S Gordon; Josep Tabernero; Rona Yaeger; Peter J O'Dwyer; Yves Humblet; Filip De Vos; A Scott Jung; Jan C Brase; Savina Jaeger; Severine Bettinger; Bijoyesh Mookerjee; Fatima Rangwala; Eric Van Cutsem
Journal:  Cancer Discov       Date:  2018-02-05       Impact factor: 39.397

6.  Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.

Authors:  Dung T Le; Jennifer N Durham; Kellie N Smith; Hao Wang; Bjarne R Bartlett; Laveet K Aulakh; Steve Lu; Holly Kemberling; Cara Wilt; Brandon S Luber; Fay Wong; Nilofer S Azad; Agnieszka A Rucki; Dan Laheru; Ross Donehower; Atif Zaheer; George A Fisher; Todd S Crocenzi; James J Lee; Tim F Greten; Austin G Duffy; Kristen K Ciombor; Aleksandra D Eyring; Bao H Lam; Andrew Joe; S Peter Kang; Matthias Holdhoff; Ludmila Danilova; Leslie Cope; Christian Meyer; Shibin Zhou; Richard M Goldberg; Deborah K Armstrong; Katherine M Bever; Amanda N Fader; Janis Taube; Franck Housseau; David Spetzler; Nianqing Xiao; Drew M Pardoll; Nickolas Papadopoulos; Kenneth W Kinzler; James R Eshleman; Bert Vogelstein; Robert A Anders; Luis A Diaz
Journal:  Science       Date:  2017-06-08       Impact factor: 47.728

7.  Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.

Authors:  Solange Peters; D Ross Camidge; Alice T Shaw; Shirish Gadgeel; Jin S Ahn; Dong-Wan Kim; Sai-Hong I Ou; Maurice Pérol; Rafal Dziadziuszko; Rafael Rosell; Ali Zeaiter; Emmanuel Mitry; Sophie Golding; Bogdana Balas; Johannes Noe; Peter N Morcos; Tony Mok
Journal:  N Engl J Med       Date:  2017-06-06       Impact factor: 91.245

8.  RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients.

Authors:  Shumei Kato; Vivek Subbiah; Erica Marchlik; Sheryl K Elkin; Jennifer L Carter; Razelle Kurzrock
Journal:  Clin Cancer Res       Date:  2016-09-28       Impact factor: 12.531

9.  Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

Authors:  Jean-Charles Soria; Yuichiro Ohe; Johan Vansteenkiste; Thanyanan Reungwetwattana; Busyamas Chewaskulyong; Ki Hyeong Lee; Arunee Dechaphunkul; Fumio Imamura; Naoyuki Nogami; Takayasu Kurata; Isamu Okamoto; Caicun Zhou; Byoung Chul Cho; Ying Cheng; Eun Kyung Cho; Pei Jye Voon; David Planchard; Wu-Chou Su; Jhanelle E Gray; Siow-Ming Lee; Rachel Hodge; Marcelo Marotti; Yuri Rukazenkov; Suresh S Ramalingam
Journal:  N Engl J Med       Date:  2017-11-18       Impact factor: 91.245

10.  Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial.

Authors:  Kiyotaka Yoh; Takashi Seto; Miyako Satouchi; Makoto Nishio; Noboru Yamamoto; Haruyasu Murakami; Naoyuki Nogami; Shingo Matsumoto; Takashi Kohno; Koji Tsuta; Katsuya Tsuchihara; Genichiro Ishii; Shogo Nomura; Akihiro Sato; Atsushi Ohtsu; Yuichiro Ohe; Koichi Goto
Journal:  Lancet Respir Med       Date:  2016-11-04       Impact factor: 30.700
  10 in total
  5 in total

1.  Kinase-mediated RAS signaling via membraneless cytoplasmic protein granules.

Authors:  Asmin Tulpule; Juan Guan; Dana S Neel; Hannah R Allegakoen; Yone Phar Lin; David Brown; Yu-Ting Chou; Ann Heslin; Nilanjana Chatterjee; Shriya Perati; Shruti Menon; Tan A Nguyen; Jayanta Debnath; Alejandro D Ramirez; Xiaoyu Shi; Bin Yang; Siyu Feng; Suraj Makhija; Bo Huang; Trever G Bivona
Journal:  Cell       Date:  2021-04-12       Impact factor: 41.582

Review 2.  RET Gene Fusions in Malignancies of the Thyroid and Other Tissues.

Authors:  Massimo Santoro; Marialuisa Moccia; Giorgia Federico; Francesca Carlomagno
Journal:  Genes (Basel)       Date:  2020-04-15       Impact factor: 4.096

Review 3.  RET in breast cancer: pathogenic implications and mechanisms of drug resistance.

Authors:  Cristiana Lo Nigro; Marta Rusmini; Isabella Ceccherini
Journal:  Cancer Drug Resist       Date:  2019-12-19

4.  Structural basis of resistance of mutant RET protein-tyrosine kinase to its inhibitors nintedanib and vandetanib.

Authors:  Simon S Terzyan; Tao Shen; Xuan Liu; Qingling Huang; Peng Teng; Mi Zhou; Frank Hilberg; Jianfeng Cai; Blaine H M Mooers; Jie Wu
Journal:  J Biol Chem       Date:  2019-05-22       Impact factor: 5.157

Review 5.  [Research Progress of Fusion Genes RET in Non-small Cell Lung Cancer].

Authors:  Yujun Zheng; Wei Jiang; Dongyan Chen; Yanjun Li; Lulu Dai; Lei Huang; Mingji Wang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2021-06-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.